Details for New Drug Application (NDA): 209296
✉ Email this page to a colleague
NDA 209296 describes CINVANTI, which is a drug marketed by Heron Theraps Inc and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug. Additional details are available on the CINVANTI profile page.
The generic ingredient in CINVANTI is aprepitant. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the aprepitant profile page.
The generic ingredient in CINVANTI is aprepitant. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the aprepitant profile page.
Summary for 209296
| Tradename: | CINVANTI |
| Applicant: | Heron Theraps Inc |
| Ingredient: | aprepitant |
| Patents: | 13 |
Suppliers and Packaging for NDA: 209296
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CINVANTI | aprepitant | EMULSION;INTRAVENOUS | 209296 | NDA | Heron Therapeutics, Inc. | 47426-201 | 47426-201-01 | 1 VIAL, GLASS in 1 CARTON (47426-201-01) / 18 mL in 1 VIAL, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | EMULSION;INTRAVENOUS | Strength | 130MG/18ML (7.2MG/ML) | ||||
| Approval Date: | Nov 9, 2017 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Sep 18, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Start Trial | Patent Expiration: | Sep 18, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY | ||||||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Sep 18, 2035 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY | ||||||||
Complete Access Available with Subscription
